Tests XB010 alone or with pembrolizumab in adults with advanced solid tumors
Tests XB010, alone or with pembrolizumab, in adults with advanced solid tumors.
Plain-language title generated from the registry record
Registry title: Study of XB010 in Subjects With Solid Tumors
Key facts
- Where
- Leicester, London, and Manchester, United KingdomSee the 4 sites
- Phase
- Phase 1
Where in United Kingdom
- University Hospitals of Leicester NHS TrustLeicester, United KingdomTaking people
- Sarah Cannon Research Institute LondonLondon, United KingdomTaking people
- University College London Hospitals NHS Foundation TrustLondon, United KingdomTaking people
- The Christie NHS Foundation TrustManchester, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Exelixis
- Trial code
- NCT06545331
- Record updated
- 30 October 2026
- Original description
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.Read full original descriptionShow less
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.
Age 18 years or older on the day of consent; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1; Adequate organ and marrow function; Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent; The Cohort Expansion stage will enroll subjects with multiple tumor types (non-small cell lung cancer, hormone-receptor-positive breast cancer, head and neck cancer, esophageal squamous cell, triple-negative breast cancer); Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.